Fiche société
Chinese PLA General Hospital
Traitements, essais et publications liés.
Traitements9programmes
Essais4liés
Publications29liées
SourceDBlocale
Traitements
9| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| CamrelizumabThis is a Phase II clinical trial for Decitabine plus Camrelizumab resistant/relapsed patients with Hodgkin Lymphoma. The purpose is to evaluate the efficacy and safety of the combination therapy of Chidamide plus Decitabine Plus Camrelizumab. | Cancer | Phase 2 | À vérifier | China | À vérifier |
| ChidamideThis is a Phase II clinical trial for Decitabine plus Camrelizumab resistant/relapsed patients with Hodgkin Lymphoma. The purpose is to evaluate the efficacy and safety of the combination therapy of Chidamide plus Decitabine Plus Camrelizumab. | Cancer | Phase 2 | À vérifier | China | À vérifier |
| DecitabineThis is a Phase II clinical trial for Decitabine plus Camrelizumab resistant/relapsed patients with Hodgkin Lymphoma. The purpose is to evaluate the efficacy and safety of the combination therapy of Chidamide plus Decitabine Plus Camrelizumab. | Cancer | Phase 2 | À vérifier | China | À vérifier |
| Microwave AblationThe goal of this clinical trial is to learn if the FlexAblate™ Ablation System works to treat a lung cancer nodules and it will also learn about the safety of the ablation system. Participants in this clinical trial will be patients aged over 18 years who have been previously diagnosed with cancer in the lung (primary or secondary malignant tumours) and deemed unsuitable for surgery or are declining surgery or, patients suitable for microwave ablation procedure based on clinical assessment. Those who meet all of the eligibility criteria at a screening assessment (a review of eligibility to participate in the study includes review of information on the cancerous nodule, recording your medical history, current medications, a blood test, and quality of life assessments) will undergo the ablation treatment with FlexAblate™ Microwave Ablation System. Follow-up assessments will be at week 1 and months 1, 3, 6 and 12 will includes CT Scans (CT or "CAT" scan is a computed tomography scan), blood tests, assessment of overall health and quality of life assessments. | Cancer | Non applicable | À vérifier | China | À vérifier |
| Surgical resectionThis phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so the CAR T cells will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Lymphodepleting chemotherapy with cyclophosphamide and fludarabine before treatment with CAR T cells may make the CAR T cells more effective. | Cancer | Non applicable | Thérapie cellulaire | China | À vérifier |
| ChidamideThis is a Phase II clinical trial for Decitabine plus Camrelizumab resistant/relapsed patients with Hodgkin Lymphoma. The purpose is to evaluate the efficacy and safety of the combination therapy of Chidamide plus Decitabine Plus Camrelizumab. | Cancer | Phase 2 | À vérifier | China | À vérifier |
| Microwave AblationThe goal of this clinical trial is to learn if the FlexAblate™ Ablation System works to treat a lung cancer nodules and it will also learn about the safety of the ablation system. Participants in this clinical trial will be patients aged over 18 years who have been previously diagnosed with cancer in the lung (primary or secondary malignant tumours) and deemed unsuitable for surgery or are declining surgery or, patients suitable for microwave ablation procedure based on clinical assessment. Those who meet all of the eligibility criteria at a screening assessment (a review of eligibility to participate in the study includes review of information on the cancerous nodule, recording your medical history, current medications, a blood test, and quality of life assessments) will undergo the ablation treatment with FlexAblate™ Microwave Ablation System. Follow-up assessments will be at week 1 and months 1, 3, 6 and 12 will includes CT Scans (CT or "CAT" scan is a computed tomography scan), blood tests, assessment of overall health and quality of life assessments. | Cancer | Non applicable | À vérifier | France, United Kingdom | À vérifier |
| Microwave AblationThe goal of this clinical trial is to learn if the FlexAblate™ Ablation System works to treat a lung cancer nodules and it will also learn about the safety of the ablation system. Participants in this clinical trial will be patients aged over 18 years who have been previously diagnosed with cancer in the lung (primary or secondary malignant tumours) and deemed unsuitable for surgery or are declining surgery or, patients suitable for microwave ablation procedure based on clinical assessment. Those who meet all of the eligibility criteria at a screening assessment (a review of eligibility to participate in the study includes review of information on the cancerous nodule, recording your medical history, current medications, a blood test, and quality of life assessments) will undergo the ablation treatment with FlexAblate™ Microwave Ablation System. Follow-up assessments will be at week 1 and months 1, 3, 6 and 12 will includes CT Scans (CT or "CAT" scan is a computed tomography scan), blood tests, assessment of overall health and quality of life assessments. | Cancer | Non applicable | À vérifier | United States | À vérifier |
| Microwave AblationThe goal of this clinical trial is to learn if the FlexAblate™ Ablation System works to treat a lung cancer nodules and it will also learn about the safety of the ablation system. Participants in this clinical trial will be patients aged over 18 years who have been previously diagnosed with cancer in the lung (primary or secondary malignant tumours) and deemed unsuitable for surgery or are declining surgery or, patients suitable for microwave ablation procedure based on clinical assessment. Those who meet all of the eligibility criteria at a screening assessment (a review of eligibility to participate in the study includes review of information on the cancerous nodule, recording your medical history, current medications, a blood test, and quality of life assessments) will undergo the ablation treatment with FlexAblate™ Microwave Ablation System. Follow-up assessments will be at week 1 and months 1, 3, 6 and 12 will includes CT Scans (CT or "CAT" scan is a computed tomography scan), blood tests, assessment of overall health and quality of life assessments. | Cancer | Non applicable | À vérifier | China | À vérifier |
Essais cliniques
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Microwave Ablation | Cancer | Non applicable | NCT04197960 | Microwave Ablation and Surgical Resection for Micropapillary Thyroid Carcinoma | COMPLETED |
| Microwave Ablation | Cancer | Non applicable | NCT02866344 | Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases | TERMINATED |
| Microwave Ablation | Cancer | Non applicable | NCT07291973 | AURORA — Clinical Investigation Evaluating the Performance, Safety and Clinical Benefit of the Endowave FlexAblate™ Microwave Ablation System in Patients Undergoing Lung Ablation Procedures. | RECRUITING |
| Chidamide | Cancer | Phase 2 | NCT04233294 | Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma | UNKNOWN |
Publications
29| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Surgical resection | Evaluation of Additional Treatment for Residual Cases After Endoscopic Papillectomy of Duodenal Ampullary Tumors. | DEN open | ||
| Surgical resection | Adverse Pathological Features and Worse Prognosis in Rectal Cancer Compared With Colon Cancer in T1 and T2 Stages. | DEN open | ||
| Surgical resection | Underestimation of Subserosal Invasion in Early Gastric Cancer-Like Advanced Gastric Carcinoma With Focal Enteroblastic Differentiation: A Case Report. | DEN open | ||
| Decitabine | Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management. | American journal of hematology | ||
| Decitabine | Defining a Therapeutic Window for Venetoclax in Post-Transplant Maintenance Therapy for High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes. | Hematological oncology | ||
| Decitabine | A survival prognostic model for high-risk myelodysplastic syndrome patients treated with decitabine. | Hematology (Amsterdam, Netherlands) | ||
| Camrelizumab | Focused ultrasound ablation surgery combined with immune checkpoint inhibition in driver-gene wild-type NSCLC with liver metastasis: a feasibility study. | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group | ||
| Camrelizumab | Cost-effectiveness of adjuvant therapy with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma: from the perspective of the Chinese healthcare system. | Annals of medicine | ||
| Chidamide | Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring. | Cancer discovery | ||
| Chidamide | Spatial proteogenomic profiling uncovers sensitization strategies for antibody-drug conjugate in HER2-positive breast cancer. | Cell reports. Medicine | ||
| Chidamide | Deubiquitinases in lung cancer: Oncogenic mechanisms, metabolic reprogramming, immune evasion, and therapeutic targeting. | Pathology, research and practice | ||
| Decitabine | DNA Methyltransferase Inhibitors, Decitabine and Guadecitabine Overcome Immune-Checkpoint Blockade Resistance and Achieve Tumor Regression in the E0771 and 4T1 Murine Models of Triple-Negative Breast Cancer. | Cancers | ||
| Camrelizumab | HAIC-Based Combination Therapy for Advanced Hepatocellular Carcinoma with Vp4 Portal Vein Tumor Thrombus and Child-Pugh B Liver Function: A Case Report. | Journal of hepatocellular carcinoma | ||
| Camrelizumab | Induction chemoimmunotherapy versus radiotherapy alone for inoperable esophageal squamous cell carcinoma: a real-world study. | Frontiers in immunology | ||
| Chidamide | Low-dose chidamide maintenance therapy following allogeneic hematopoietic cell transplantation in T-cell acute lymphoblastic leukemia or lymphomas: a phase II, open-label, multicenter, single-arm trial. | The Lancet regional health. Western Pacific | ||
| Chidamide | Acute lymphoblastic leukemia presenting as myocardial infiltration mimicking hypertrophic cardiomyopathy: a case report. | Frontiers in oncology | ||
| Chidamide | Chidamide‑augmented BEAM conditioning and maintenance in first-remission T‑cell lymphoma: a single‑arm phase 2 experience. | Bone marrow transplantation | ||
| Decitabine | Gastrointestinal adverse reactions and metabolism-nutrition disorders associated with hypomethylating agents: a pharmacovigilance study with exploratory mechanistic analysis. | Frontiers in nutrition | ||
| Decitabine | Successful allogeneic hematopoietic stem cell transplantation in children with myeloid malignancies secondary to GATA2 deficiency using decitabine-containing busulfan conditioning. | Bone marrow transplantation | ||
| Camrelizumab | Camrelizumab combined with chemotherapy as postoperative adjuvant therapy after radical surgery for cervical cancer patients with pathologically positive lymph nodes: a prospective multicenter phase II clinical trial. | Journal of gynecologic oncology | ||
| Chidamide | Low-Dose Chidamide Maintenance Therapy After Hematopoietic Stem Cell Transplantation for T-Cell Acute Lymphoblastic Leukemia: A Case Series. | Hematological oncology | ||
| Camrelizumab | Efficacy at a cost: camrelizumab and famitinib within the expanding landscape of combination therapies. | Gynecology and pelvic medicine | ||
| Camrelizumab | Immune checkpoint inhibitor integration in locoregionally advanced nasopharyngeal carcinoma: a prospective evidence synthesis on efficacy, safety, and therapeutic optimization. | Frontiers in immunology | ||
| Chidamide | Dual resistance to asparaginase and PD-1 blockade in extranodal natural killer/T-cell lymphoma: dismal outcomes from a multicenter cohort. | Haematologica | ||
| Chidamide | MRD-driven HDACi-based therapy post-transplant: a real-world study in high-risk acute myeloid leukemia. | Annals of hematology | ||
| Decitabine | Identification of FOXK1 and SEMA7A as key genes associated with mA-related programmed cell death in diabetic retinopathy. | Hereditas | ||
| Decitabine | Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21. | Blood neoplasia | ||
| Camrelizumab | Clinical Efficacy of Modified San'ao Decoction and Erchen Decoction for Esophageal Dysphagia (Shi Bi) with Phlegm-Dampness and Blood Stasis Syndrome. | Journal of visualized experiments : JoVE | ||
| Camrelizumab | Real-world efficacy and safety of PD-1 inhibitors in patients living with HIV and cancer: a retrospective cohort study. | Frontiers in oncology |